ライフサイエンスコーパス: sedative-hypnotic

1 e serotonin reuptake inhibitors) and 27.4% a sedative/hypnotic.

2 for severe anxiety that was unresponsive to sedative hypnotics.

3 it mediate sedation and serve as targets for sedative hypnotics.

4 novel aspects of neurobiological response to sedative-hypnotics.

5 e sedation and need for constant infusion of sedative-hypnotics.

6 ntly increasing the use of antipsychotics or sedative-hypnotics.

7 nstitute the majority of clinically relevant sedative-hypnotics.

8 Etomidate is a nonbarbiturate sedative hypnotic agent with no analgesic properties.

9 Propofol is also a sedative hypnotic agent with rapid onset and short durat

10 e of anesthesiology are employing new potent sedative hypnotic agents to accomplish effective pediatr

11 al uses as anticonvulsants, anxiolytics, and sedative-hypnotic agents.

12 ion and have been implicated in responses to sedative/hypnotic agents (including neuroactive steroids

13 ious studies have shown that a wide range of sedative/hypnotic agents, including ethanol, induce slee

14 -4(3H)-quinazolinone, Quaalude), an infamous sedative-hypnotic and recreational drug from the 1960s-1

15 in a wide variety of behavioral responses to sedative-hypnotics and may directly facilitate progress

16 Anxiolytic/sedative/hypnotic and antidepressant medication use were

17 zodiazepines, which are often used for their sedative/hypnotic and anxiolytic effects.

18 Particularly addressing the fields of sedatives, hypnotics and neuromuscular blockers, however

19 he target of a structurally diverse group of sedative, hypnotic, and anesthetic drugs, including the

20 currents and to test their contributions to sedative, hypnotic, and immobilizing anesthetic actions.

21 Daily doses of all opioid, sedative, hypnotic, and major tranquilizer drugs adminis

22 r 2 or more antidepressants, antipsychotics, sedative-hypnotics, and antidepressant-antipsychotic com

23 Chlormethiazole has sedative, hypnotic, anticonvulsant and neuroprotective p

24 lated by the anxiolytic, anticonvulsant, and sedative-hypnotic benzodiazepines.

25 justed RR, 1.87; 95% CI, 1.70-2.06), receive sedative hypnotics concurrently (40.7% vs 7.6%, adjusted

26 Propofol is the most commonly used sedative-hypnotic drug for noxious procedures, yet the m

27 n mice, but it should be applicable to other sedative/hypnotic drugs and to testing cerebellar mutant

28 However, we show that the ability of sedative/hypnotic drugs to enhance tonic inhibition in t

29 ptor numbers when considering the ability of sedative/hypnotic drugs to enhance tonic inhibition.

30 hanced by neurosteroids, antiepileptics, and sedative/hypnotic drugs.

31 th neuronal development and tolerance to the sedative-hypnotic effects of GABA(A)R positive modulator

32 BA-gated channels, and thereby achieve their sedative-hypnotic effects.

33 could play a role in their immobilizing and sedative-hypnotic effects.

34 eficient mice are also less sensitive to the sedative/hypnotic effects of ethanol, as shown by more r

35 o behavioral intoxication, as assayed by the sedative/hypnotic effects of ethanol.

36 ce for ethanol and are more sensitive to the sedative/hypnotic effects of this drug than controls.

37 iled to develop rapid tolerance to ethanol's sedative/hypnotic effects.

38 mplex traits, including diverse responses to sedative-hypnotics, have been detected on distal chromos

39 ntial toxicity from accentuated responses to sedative hypnotics in active cocaine-abusing subjects.

40 tential as anxiolytics, anticonvulsants, and sedative/hypnotics is limited by rapid metabolism.

41 Patients may use sedatives, hypnotics, or alcohol in an effort to interru

42 al ventilation (TV) and exposure to opioids, sedatives-hypnotics, or general anaesthetics in neonates

43 management of the surgical patient for their sedative/hypnotic properties although the alpha2 adrenoc

44 ht underlie the increased sensitivity to the sedative/hypnotic properties of ethanol but not the rewa

45 and prolonged hypotensive, bradycardic, and sedative-hypnotic responses to alpha(2)AR stimulation.

46 f the delta subunit to GABA pharmacology and sedative/hypnotic responses and behavior and provide ins

47 visits in which neither antidepressants nor sedative/hypnotics were prescribed.

48 R, 15.46; 99% CI, 6.77-35.31); and 2 or more sedative-hypnotics, with anxiety disorders (OR, 2.13; 99

49 RK3 (Kir3.3), is associated with less severe sedative-hypnotic withdrawal.

50 thdrawal from pentobarbital as well as other sedative-hypnotics (zolpidem and ethanol) versus wild-ty